A multicenter survey of temporal changes in chemotherapy-induced hair loss in breast cancer patients

被引:30
作者
Watanabe, Takanori [1 ]
Yagata, Hiroshi [2 ]
Saito, Mitsue [3 ]
Okada, Hiroko [4 ]
Yajima, Tamiko [5 ]
Tamai, Nao [6 ]
Yoshida, Yuko [7 ]
Takayama, Tomoko [8 ]
Imai, Hirohisa [9 ]
Nozawa, Keiko [10 ]
Sangai, Takafumi [11 ]
Yoshimura, Akiyo [12 ]
Hasegawa, Yoshie [13 ]
Yamaguchi, Takuhiro [14 ]
Shimozuma, Kojiro [15 ]
Ohashi, Yasuo [16 ]
机构
[1] Natl Hosp Org Sendai Med Ctr, Dept Breast Canc, Sendai, Miyagi, Japan
[2] Saitama Med Univ, Saitama Med Ctr, Dept Breast Care, Kawagoe, Saitama, Japan
[3] Juntendo Univ, Dept Breast Oncol, Tokyo, Japan
[4] Univ Tokyo, Grad Sch Med, Dept Hlth Commun, Tokyo, Japan
[5] EP CRSU Co Ltd, Clin Res Promot Dept, Tokyo, Japan
[6] Univ Tokyo, Grad Sch Med, Div Hlth Sci & Nursing, Tokyo, Japan
[7] Juntendo Univ Hosp, Dept Breast Oncol, Tokyo, Japan
[8] Natl Canc Ctr, Ctr Canc Control & Informat Serv, Canc Informat Serv Div, Tokyo, Japan
[9] Univ Tokyo, Grad Sch Med, Dept Med & Pharmaceut Community Healthcare, Tokyo, Japan
[10] Natl Canc Ctr, Appearance Support Ctr, Tokyo, Japan
[11] Chiba Univ, Grad Sch Med, Dept Gen Surg, Chiba, Japan
[12] Aichi Canc Hosp, Dept Breast Oncol, Nagoya, Aichi, Japan
[13] Hirosaki Municipal Hosp, Dept Breast Surg, Hirosaki, Aomori, Japan
[14] Tohoku Univ, Grad Sch Med, Div Biostat, Sendai, Miyagi, Japan
[15] Ritsumeikan Univ, Coll Life Sci, Dept Biomed Sci, Kusatsu, Japan
[16] Chuo Univ, Dept Integrated Sci & Engn Sustainable Soc, Tokyo, Japan
关键词
INDUCED ALOPECIA; RECEIVING END; DOCETAXEL; PACLITAXEL; PERCEPTIONS; PREVENTION; EFFICACY; TAXANE; WOMEN;
D O I
10.1371/journal.pone.0208118
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose Many breast cancer patients suffer from chemotherapy-induced hair loss. Accurate information about temporal changes in chemotherapy-induced hair loss is important for supporting patients scheduled to receive chemotherapy, because it helps them to prepare. However, accurate information, on issues such as the frequency of hair loss after chemotherapy, when regrowth starts, the condition of regrown hair, and the frequency of incomplete hair regrowth, is lacking. This study aimed to clarify the long-term temporal changes in chemotherapy-induced hair loss using patient-reported outcomes for chemotherapy-induced hair loss. Methods We conducted a multicenter, cross-sectional questionnaire survey. Disease-free patients who had completed adjuvant chemotherapy consisting of anthracycline and/or taxanes for breast cancer within the prior 5 years were enrolled from 47 hospitals and clinics in Japan. Descriptive statistics were obtained in this study. The study is reported according to the STROBE criteria. Results The response rate was 81.5% (1511/1853), yielding 1478 questionnaires. Hair loss occurred in 99.9% of patients. The mean time from chemotherapy until hair loss was 18.0 days. Regrowth of scalp hair occurred in 98% of patients. The mean time from the completion of chemotherapy to the beginning of regrowth was 3.3 months. Two years after chemotherapy completion, the scalp-hair recovery rate was <30% in approximately 4% of patients, and this rate showed no improvement 5 years after chemotherapy. Eighty-four percent of the patients initially used wigs, decreasing to 47% by 1 year after chemotherapy and 15.2% after 2 years. The mean period of wig use was 12.5 months. However, a few patients were still using wigs 5 years after completing chemotherapy. Conclusions Our survey focused on chemotherapy-induced hair loss in breast cancer patients. We believe these results to be useful for patients scheduled to receive chemotherapy.
引用
收藏
页数:12
相关论文
共 30 条
[1]   Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types [J].
Aapro, Matti S. ;
Schmoll, Hans J. ;
Jahn, Franziska ;
Carides, Alexandra D. ;
Webb, R. Timothy .
CANCER TREATMENT REVIEWS, 2013, 39 (01) :113-117
[2]   Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials [J].
Albain, K. ;
Anderson, S. ;
Arriagada, R. ;
Barlow, W. ;
Bergh, J. ;
Bliss, J. ;
Buyse, M. ;
Cameron, D. ;
Carrasco, E. ;
Clarke, M. ;
Correa, C. ;
Coates, A. ;
Collins, R. ;
Costantino, J. ;
Cutter, D. ;
Cuzick, J. ;
Darby, S. ;
Davidson, N. ;
Davies, C. ;
Davies, K. ;
Delmestri, A. ;
Di Leo, A. ;
Dowsett, M. ;
Elphinstone, P. ;
Evans, V. ;
Ewertz, M. ;
Gelber, R. ;
Gettins, L. ;
Geyer, C. ;
Goldhirsch, A. ;
Godwin, J. ;
Gray, R. ;
Gregory, C. ;
Hayes, D. ;
Hill, C. ;
Ingle, J. ;
Jakesz, R. ;
James, S. ;
Kaufmann, M. ;
Kerr, A. ;
MacKinnon, E. ;
McGale, P. ;
McHugh, T. ;
Norton, L. ;
Ohashi, Y. ;
Paik, S. ;
Pan, H. C. ;
Perez, E. ;
Peto, R. ;
Piccart, M. .
LANCET, 2012, 379 (9814) :432-444
[3]  
American Cancer Society, 2017, CANC FACTS FIG 2017
[4]   Hair and cancer chemotherapy: consequences and nursing care - a literature study [J].
Batchelor, D .
EUROPEAN JOURNAL OF CANCER CARE, 2001, 10 (03) :147-163
[5]   Changing patient perceptions of the side effects of cancer chemotherapy [J].
Carelle, N ;
Piotto, E ;
Bellanger, A ;
Germanaud, J ;
Thuillier, A ;
Khayat, D .
CANCER, 2002, 95 (01) :155-163
[6]   ON THE RECEIVING END PATIENT PERCEPTION OF THE SIDE-EFFECTS OF CANCER-CHEMOTHERAPY [J].
COATES, A ;
ABRAHAM, S ;
KAYE, SB ;
SOWERBUTTS, T ;
FREWIN, C ;
FOX, RM ;
TATTERSALL, MHN .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (02) :203-208
[7]   Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer [J].
Di Leo, Angelo ;
Gomez, Henry L. ;
Aziz, Zeba ;
Zvirbule, Zanete ;
Bines, Jose ;
Arbushites, Michael C. ;
Guerrera, Stephanie F. ;
Koehler, Maria ;
Oliva, Cristina ;
Stein, Steven H. ;
Williams, Lisa S. ;
Dering, Judy ;
Finn, Richard S. ;
Press, Michael F. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) :5544-5552
[8]  
Dorr VJ, 1998, SEMIN ONCOL, V25, P562
[9]   Successful reduction of alopecia induced by anthracycline and taxane containing adjuvant chemotherapy in breast cancer - clinical evaluation of sensor-controlled scalp cooling [J].
Friedrichs, Kay ;
Carstensen, Martin H. .
SPRINGERPLUS, 2014, 3
[10]  
Griffin AM, 1996, ANN ONCOL, V7, P189